Ken Griffin Phathom Pharmaceuticals, Inc. Transaction History

Citadel Advisors LLC

$505 Billion
Q3 2024

A detailed history of Ken Griffin (Citadel Advisors LLC) transactions in Phathom Pharmaceuticals, Inc. stock. As of the latest transaction made, Citadel Advisors LLC holds 18,200 shares of PHAT stock, worth $136,500. This represents 0.0% of its overall portfolio holdings.

Number of Shares

18,200

Previous 2,500 628.0%

Holding current value

$136,500

Previous $25,000 1216.0%

% of portfolio

0.0%

Previous 0.0%

17 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	BUY	$10.25 - $19.5 $1.45 Million - $2.76 Million	141,587 Added 179.64%	220,403 $3.98 Million
Q2 2024 Aug 14, 2024	SELL	$8.97 - $12.05 $420,056 - $564,289	-46,829 Reduced 37.27%	78,816 $811,000
Q1 2024 May 15, 2024	BUY	$6.21 - $11.05 $708,635 - $1.26 Million	114,112 Added 989.44%	125,645 $1.33 Million
Q4 2023 Feb 14, 2024	SELL	$6.99 - $10.71 $1.85 Million - $2.83 Million	-264,194 Reduced 95.82%	11,533 $105,000
Q3 2023 Nov 14, 2023	BUY	$10.26 - $15.7 $2.66 Million - $4.06 Million	258,812 Added 1530.07%	275,727 $2.86 Million
Q2 2023 Aug 14, 2023	SELL	$7.28 - $14.32 $1.25 Million - $2.46 Million	-171,569 Reduced 91.03%	16,915 $242,000
Q1 2023 May 15, 2023	BUY	$6.19 - $12.36 $1.16 Million - $2.31 Million	186,731 Added 10652.08%	188,484 $1.35 Million
Q4 2022 Feb 14, 2023	BUY	$9.18 - $11.53 $16,092 - $20,212	1,753 New	1,753 $19,000
Q2 2022 Aug 15, 2022	BUY	$6.2 - $15.5 $83,985 - $209,963	13,546 Added 118.14%	25,012 $212,000
Q4 2021 Feb 14, 2022	SELL	$17.83 - $33.15 $141,641 - $263,343	-7,944 Reduced 40.93%	11,466 $225,000
Q3 2021 Nov 15, 2021	SELL	$30.69 - $36.83 $1.87 Million - $2.25 Million	-60,964 Reduced 75.85%	19,410 $623,000
Q2 2021 Aug 16, 2021	BUY	$32.66 - $39.87 $2.35 Million - $2.86 Million	71,833 Added 841.04%	80,374 $2.72 Million
Q1 2021 May 17, 2021	SELL	$33.86 - $48.68 $119,695 - $172,083	-3,535 Reduced 29.27%	8,541 $321,000
Q4 2020 Feb 16, 2021	BUY	$33.22 - $50.26 $178,059 - $269,393	5,360 Added 79.81%	12,076 $401,000
Q3 2020 Nov 16, 2020	BUY	$29.24 - $40.19 $196,375 - $269,916	6,716 New	6,716 $246,000
Q2 2020 Aug 14, 2020	SELL	$25.06 - $54.6 $299,416 - $652,360	-11,948 Closed	0 $0
Q1 2020 May 15, 2020	BUY	$24.65 - $42.83 $294,518 - $511,732	11,948 New	11,948 $308,000

Others Institutions Holding PHAT

# of Institutions

144

Shares Held

73.6M

Call Options Held

42.3K

Put Options Held

45.7K

View Full List

About Phathom Pharmaceuticals, Inc.

Ticker PHAT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 39,175,200
Market Cap $294M
Description
Phathom Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. The company has the rights in the United States, Europe, and Canada to vonoprazan, a potassium-competitive acid blocker (P-CAB) that blocks acid secretion in the stomach. It is also develo...

More about PHAT

Track Ken Griffin's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.

Account